Janssen and Johnson & Johnson to Present Results from Five Pivotal Phase 3 Studies Evaluating Investigational Canagliflozin for the Treatment of Type 2 Diabetes

NEW BRUNSWICK, N.J., June 5, 2012 /PRNewswire/ -- Janssen and Johnson & Johnson (NYSE: JNJ) will provide investors and other interested parties an overview presentation of results from five pivotal Phase 3 studies evaluating investigational canagliflozin for the treatment of Type 2 Diabetes on Sunday, June 10 at approximately 2:00 p.m., Eastern Time. These data will be presented at the American Diabetes Association annual meeting in Philadelphia, Pa.

The presentation can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations."

SOURCE Johnson & Johnson

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED